This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with Treatment Emergent Adverse Events (TEAEs), Overall and by severity, seriousness and relationship to Investigational Product (IP)
Timeframe: From baseline up to Week 75
Percentage of participants with TEAEs Overall and by severity, seriousness and relationship to IP
Timeframe: From baseline up to Week 75
Number of participants with Adverse Events of Special Interest (AESI)
Timeframe: From baseline up to Week 75
Percentage of participants with AESI
Timeframe: From baseline up to Week 75
Number of participants with clinically relevant changes from baseline in laboratory assessments and vital signs
Timeframe: From baseline up to Week 75
Percentage of participants with clinically relevant changes from baseline in laboratory assessments and vital signs
Timeframe: From baseline up to Week 75